Furthermore, in the NSCLC cells the AMPK activator inhibited cell proliferation and migration, which were tested by EdU incorporation (results quantified in Fig. 1H) and “Transwell” (results quantified in Fig. 1I) assays, respectively. Here, PRKAA1 is linked to non-small cell lung carcinoma.